Table 3

Performance of the identified cut-offs at first follow-up or regular screening after initial detection (n=437; 412 benign nodules and 25 lung cancer nodules)

All new solid nodules that persisted at first LDCT after detectionSubsequent LDCT within 120 days (short-term follow-up)Subsequent LDCT after 120 days
VDT ≤590 days
 Sensitivity (95% CI)23/25, 92.0% (73.9 to 98.9)15/17, 88.2% (64.4 to 98.0)8/8, 100% (62.8 to 100)
 Specificity (95% CI)360/412, 87.4% (83.8 to 90.3)137/178, 77.0% (70.2 to 82.6)223/234, 95.3% (91.7 to 97.4)
 PPV (95% CI)23/75, 30.7% (21.3 to 41.9)15/56, 26.8% (17.5 to 41.0)8/19, 42.1% (23.1 to 63.8)
 NPV (95% CI)360/362, 99.4% (97.9 to 100)137/139, 98.6% (94.6 to 99.9)223/223, 100% (98.0 to 100)
Volume ≥65 mm3
 Sensitivity (95% CI)24/25, 96.0% (78.9 to 100)16/17, 94.1% (71.1 to 100)8/8, 100% (62.8 to 100)
 Specificity (95% CI)313/412, 76.0% (71.6 to 79.9)94/178, 52.8% (45.5 to 60.0)219/234, 93.6% (89.6 to 96.2)
 PPV (95% CI)24/123, 19.5% (13.4 to 27.5)16/100, 16.0% (10.0 to 24.5)8/23, 34.8% (18.7 to 55.2)
 NPV (95% CI)313/314, 99.7% (98.0 to 100)94/95, 98.9% (93.7 to 100)219/219, 100% (97.9 to 100)
VDT ≤590 days or volume ≥200 mm3
 Sensitivity (95% CI)25/25, 100.0% (84.2 to 100)17/17, 100.0% (78.4 to 100)8/8, 100% (62.8 to 100)
 Specificity (95% CI)345/412, 83.7% (79.9 to 87.0)124/178, 69.7% (62.5 to 76.0)221/234, 94.4% (90.6 to 96.8)
 PPV (95% CI)25/92, 27.2% (19.1 to 37.1)17/71, 24.6% (15.9 to 36.0)8/21, 38.1% (20.7 to 59.2)
 NPV (95% CI)345/345, 100.0% (98.7 to 100)124/124, 100.0% (96.4 to 100)221/221, 100.0% (97.9 to 100)
  • Exact volume measurement was not available or classification based on the radiologist’s size categorisation was unattainable for 17 benign nodules, and they were not included in the calculations.

  • LDCT, low-dose CT; NPV, negative predictive value; PPV, positive predictive value; VDT, volume doubling time.